Matsumura-Nakano Y, et al. - In this prospective, multicenter, open-label, non-inferiority trial, researchers assessed the efficacy of oral anticoagulation (OAC) alone without antiplatelet therapy (APT) in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) beyond 1 year after coronary stenting. Patients were randomized (1:1) to receive OAC alone or OAC in combination with single APT, and were analyzed for primary endpoint (ie, a composite of all-cause death, myocardial infarction, stroke, or systemic embolism). They performed a median follow-up of 2.5 years, during which they reported the occurrence of the primary endpoint in 54 patients in the OAC alone group and in 47 patients in the OAC plus APT group. Overall, no non-inferiority of OAC alone to combined OAC and APT was established in patients with AF and stable CAD beyond 1 year after stenting.